Pharmacological Management of Diabetes

Correct Answer

C — Pioglitazone

Rationale

Pioglitazone is a thiazolidinedione, along with rosiglitazone. Sitagliptin is a dipeptidyl peptidase-4 inhibitor. Metformin is a biguanide. Repaglinide is a meglitinide.

Correct Answer

A — Sitagliptin

Rationale

Sitagliptin is a dipeptidyl peptidase-4 inhibitor, along with saxagliptin, linagliptin, and alogliptin. Pioglitazone is a thiazolidinedione. Glipizide is a second-generation sulfonylurea. Acarbose is an alpha-glucosidase inhibitor.

Correct Answer

D — Acarbose

Rationale

Acarbose is an alpha-glucosidase inhibitor, along with miglitol. Linagliptin is a dipeptidyl peptidase-4 inhibitor. Metformin is a biguanide. Pioglitazone is a thiazolidinedione.

Correct Answer

B — Thiazolidinedione

Rationale

Rosiglitazone is classified as a thiazolidinedione, along with pioglitazone. Dipeptidyl peptidase-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. Meglitinides include repaglinide and nateglinide. Metformin is the only biguanide in current clinical use.

Correct Answer

A — Dipeptidyl peptidase-4 inhibitor

Rationale

Linagliptin is classified as a dipeptidyl peptidase-4 inhibitor, along with sitagliptin, saxagliptin, and alogliptin. Thiazolidinediones include pioglitazone and rosiglitazone. Alpha-glucosidase inhibitors include acarbose and miglitol. Metformin is a biguanide.

Correct Answer

C — Alpha-glucosidase inhibitor

Rationale

Miglitol is classified as an alpha-glucosidase inhibitor, along with acarbose. Dipeptidyl peptidase-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. Sulfonylureas include glipizide, glyburide, and glimepiride. Thiazolidinediones include pioglitazone and rosiglitazone.

Correct Answer

B — Pioglitazone acts by activating a nuclear receptor that regulates gene transcription; the resulting changes in insulin-sensitizing protein expression require weeks to develop

Rationale

Thiazolidinediones such as pioglitazone activate peroxisome proliferator-activated receptor gamma, a nuclear receptor. This receptor, once activated, regulates the transcription of genes involved in glucose and lipid metabolism — including glucose transporter type 4 and adiponectin. Because the effect depends on changes in gene transcription and the subsequent accumulation of newly synthesized proteins, the full pharmacological response requires several weeks to manifest. This contrasts with sulfonylureas, which close potassium channels within minutes, and metformin, which inhibits mitochondrial complex I acutely. Pioglitazone reaches steady-state plasma concentrations within days; the delay is mechanistic, not pharmacokinetic. No prodrug conversion is required for thiazolidinedione activity.

Correct Answer

D — Sitagliptin inhibits the enzyme that degrades glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, raising active incretin levels and prolonging their postprandial effect on beta cells

Rationale

Dipeptidyl peptidase-4 is the enzyme responsible for rapid degradation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide; the half-life of glucagon-like peptide-1 in plasma is only 1 to 2 minutes. Sitagliptin inhibits this enzyme, raising active incretin levels two- to threefold and prolonging their postprandial stimulation of insulin secretion from beta cells. Because incretin-mediated insulin secretion is glucose-dependent — it ceases when blood glucose returns to fasting levels — sitagliptin carries very low hypoglycemia risk as monotherapy. Sitagliptin does not bind or activate glucagon-like peptide-1 receptors directly (that is the mechanism of glucagon-like peptide-1 receptor agonists), does not close potassium channels, and does not stimulate incretin secretion from intestinal cells.

Correct Answer

A — Peroxisome proliferator-activated receptor gamma activation in the kidney increases renal sodium reabsorption, expanding plasma volume and causing peripheral edema

Rationale

Peroxisome proliferator-activated receptor gamma is expressed in renal collecting duct cells in addition to adipose tissue. Thiazolidinedione activation of renal peroxisome proliferator-activated receptor gamma upregulates sodium reabsorption channels in the collecting duct, increasing sodium and water retention. The resulting plasma volume expansion leads to peripheral edema, occurring in 5 to 15 percent of patients. This mechanism — not aldosterone stimulation, capillary permeability changes, or hepatic protein effects — is the established basis for thiazolidinedione-associated fluid retention, and explains why thiazolidinediones are contraindicated in patients with New York Heart Association class 3 or class 4 heart failure.

Correct Answer

C — The incretin hormones preserved by dipeptidyl peptidase-4 inhibitors stimulate insulin secretion only when blood glucose is elevated; when glucose returns to fasting levels the incretin effect ceases, preventing further insulin release

Rationale

The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide amplify insulin secretion from beta cells in a glucose-dependent manner — their effect is active when blood glucose is elevated postprandially and diminishes as glucose normalizes. Dipeptidyl peptidase-4 inhibitors raise active incretin levels by blocking the enzyme that degrades them, but because the underlying incretin mechanism is glucose-dependent, insulin secretion is not driven below the normal fasting range. This is the fundamental pharmacological difference from sulfonylureas, which close adenosine triphosphate-sensitive potassium channels independent of blood glucose. Dipeptidyl peptidase-4 inhibitors do not stimulate glucagon, do not alter counter-regulatory thresholds, and produce a qualitatively different type of insulin secretion than sulfonylureas rather than simply less of the same stimulus.

Correct Answer

B — Linagliptin is eliminated primarily by biliary excretion rather than renal excretion, so renal impairment does not cause it to accumulate

Rationale

Linagliptin is unique among the dipeptidyl peptidase-4 inhibitors in that it is excreted primarily through bile and feces rather than through the kidney. Because its elimination does not depend on renal function, linagliptin plasma levels are not meaningfully affected by even severe renal impairment, and no dose adjustment is required across any stage of chronic kidney disease. Sitagliptin and saxagliptin are renally eliminated and accumulate when glomerular filtration rate is reduced, requiring dose reduction to avoid drug accumulation. Receptor potency, cytochrome P450 metabolism, and protein binding differences are not the relevant mechanism for linagliptin's renal safety advantage.

Correct Answer

D — Pioglitazone shifts mesenchymal stem cell differentiation away from osteoblasts and toward adipocytes by activating peroxisome proliferator-activated receptor gamma, reducing bone formation

Rationale

Mesenchymal stem cells in bone marrow are the common precursor for both osteoblasts and adipocytes. Peroxisome proliferator-activated receptor gamma activation strongly promotes adipocyte differentiation and simultaneously diverts stem cells away from the osteoblast lineage, reducing the pool of bone-forming cells. Over time this impairs bone remodeling and reduces bone mineral density. Pioglitazone does not reduce intestinal calcium absorption, increase renal calcium excretion, or directly activate osteoclasts — the mechanism is a diversion of stem cell fate toward fat rather than bone.

Correct Answer

A — Acarbose inhibits brush border alpha-glucosidase enzymes in the small intestine, leaving undigested carbohydrates to pass into the colon where bacterial fermentation produces gas and short-chain fatty acids

Rationale

Alpha-glucosidase enzymes on the brush border of small intestinal enterocytes — including sucrase, maltase, and glucoamylase — cleave complex carbohydrates into absorbable monosaccharides. Acarbose competitively inhibits these enzymes, slowing but not completely blocking carbohydrate digestion. The undigested oligosaccharides and disaccharides that reach the colon are fermented by resident bacteria, producing hydrogen and carbon dioxide gas, short-chain fatty acids, and osmotic effects that collectively cause flatulence, bloating, and diarrhea. Acarbose is minimally absorbed and has no systemic inflammatory activity. It acts on brush border glucosidases, not pancreatic amylase. It does not bind bile acids.

Correct Answer

C — Acarbose inhibits the intestinal enzymes needed to digest sucrose into absorbable glucose and fructose, so the sucrose in orange juice cannot be absorbed quickly enough to correct hypoglycemia

Rationale

Orange juice contains sucrose, which must be cleaved by the brush border enzyme sucrase into glucose and fructose before absorption can occur. Acarbose inhibits sucrase along with other alpha-glucosidase enzymes, so sucrose in orange juice or other sucrose-containing foods cannot be rapidly digested and absorbed when acarbose is on board. Hypoglycemia in a patient taking an alpha-glucosidase inhibitor must therefore be treated with pure glucose — glucose tablets or gel — which is absorbed directly without requiring enzymatic digestion. The delay in sucrose absorption can allow hypoglycemia to persist and worsen. Orange juice composition, acidity, and glucagon-like peptide-1 effects are not the reason for this specific treatment rule.

Correct Answer

B — Pioglitazone activates renal peroxisome proliferator-activated receptor gamma, increasing sodium retention and worsening volume overload, whereas sitagliptin does not cause fluid retention

Rationale

Thiazolidinediones such as pioglitazone activate peroxisome proliferator-activated receptor gamma in renal collecting duct cells, upregulating sodium reabsorption and expanding plasma volume. In a patient with New York Heart Association class 3 heart failure who is already volume-overloaded, this additional fluid retention can precipitate acute decompensation. Pioglitazone is contraindicated in New York Heart Association class 3 and class 4 heart failure for this reason. Sitagliptin, by blocking dipeptidyl peptidase-4 to raise active incretin levels, operates through a mechanism that does not involve sodium or fluid homeostasis, making it appropriate in this patient. Pioglitazone does not depress cardiac contractility via calcium channels or activate the renin-angiotensin-aldosterone system; its heart failure risk is entirely mediated by fluid retention.

Correct Answer

D — Sitagliptin

Rationale

This patient has developed new heart failure, likely precipitated by pioglitazone's activation of renal peroxisome proliferator-activated receptor gamma driving sodium retention and volume expansion. After stopping pioglitazone, the replacement must not worsen volume overload. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, enhances incretin-mediated glucose-dependent insulin secretion without involving sodium or fluid homeostasis, making it appropriate in heart failure. Rosiglitazone is also a thiazolidinedione sharing the same peroxisome proliferator-activated receptor gamma-mediated sodium retention mechanism as pioglitazone and is equally contraindicated in heart failure. Glipizide and repaglinide are insulin secretagogues without the fluid retention mechanism, but among the options given, sitagliptin is the agent most specifically selected on the basis of having no mechanism that worsens volume overload in a patient whose decompensation was driven by sodium retention.

Correct Answer

A — Sitagliptin — dipeptidyl peptidase-4 inhibition raises active glucagon-like peptide-1 levels, which have trophic effects on the pancreatic ductal epithelium that may promote inflammation

Rationale

Pancreatitis is a rare but documented adverse effect associated with dipeptidyl peptidase-4 inhibitors across the class. The proposed mechanism involves the trophic effects of elevated glucagon-like peptide-1 on the pancreatic ductal epithelium — glucagon-like peptide-1 receptors are expressed on ductal cells, and sustained elevation of active glucagon-like peptide-1 from dipeptidyl peptidase-4 inhibition may contribute to ductal cell proliferation and inflammation in susceptible individuals. The clinical guideline is to hold the dipeptidyl peptidase-4 inhibitor if acute pancreatitis is suspected and not restart it after recovery. Pioglitazone does not have a known mechanism linking peroxisome proliferator-activated receptor gamma activation to pancreatitis — neither acinar zymogen disruption nor intraductal fluid retention are established effects. The absence of gallstones or biliary dilation on imaging in this patient makes gallstone pancreatitis unlikely, supporting a drug-related cause from the dipeptidyl peptidase-4 inhibitor.

Correct Answer

C — Linagliptin is eliminated primarily by biliary excretion rather than renal excretion, so its plasma levels are not affected by reduced glomerular filtration rate and no dose adjustment is required

Rationale

Linagliptin is excreted primarily through the bile and feces, making its clearance independent of renal function. At an estimated glomerular filtration rate of 22 mL/min — severe renal impairment — sitagliptin would accumulate to elevated levels and require a substantially reduced dose to avoid toxicity, adding prescribing complexity and risk of error. Linagliptin can be prescribed at its standard dose without adjustment across all stages of chronic kidney disease, making it the preferred dipeptidyl peptidase-4 inhibitor in this patient. The difference is in elimination route, not receptor potency, metabolite activity, or isoform selectivity.